Delving into the Latest Updates on Ergometrine Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide, 9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8β(S)-carboxamide, 9,10-didehydro-N-(α-(hydroxymethyl)ethyl)-6-methylergoline-8-β-carboxamide

+ [16]

Target

α-adrenergic receptor

Mechanism

α-adrenergic receptor agonists(Alpha adrenergic receptor agonists)

Therapeutic Areas

Urogenital Diseases

Active Indication

Uterine Hemorrhage

Inactive Indication-

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Tianjin Jinyao Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 May 1971),

Uterine Hemorrhage

Regulation-

Login to view timeline

Structure

Molecular FormulaC23H27N3O6

InChIKeyYREISLCRUMOYAY-IIPCNOPRSA-N

CAS Registry129-51-1

This study will investigate the effects of drugs called "uterotonics" that help with the contraction of the uterus after a baby is born. This uterine contraction is very important to stop the bleeding after delivery. An uncontracted uterine state is called "uterine atony", which can lead to an excessive amount of post-delivery bleeding. Carbetocin is an uterotonic drug that works well to prevent post-delivery bleeding. In some cases, carbetocin is not enough to contract the uterus, and ongoing bleeding continues. When that happens, there are other uterotonic medications that can be used. In this study, we aim to find which uterotonic drug, amongst those available (oxytocin, carbetocin, ergometrine or carboprost), is more effective to lower the risk of post-delivery bleeding once carbetocin has already been administered.
This study will be done by using a very small sample of uterine tissue, taken from the incision site, following delivery by cesarean section. The sample is taken to the laboratory and will be exposed to carbetocin followed by other uterotonic drugs. The information obtained from this study will help modify the treatment for uterine atony and post-delivery bleeding to lower the risk further.

Start Date04 Apr 2024

Sponsor / Collaborator

Samuel Lunenfeld Research Institute

ACTRN12618001811291 / Not yet recruitingNot ApplicableIIT

SECTION Study: Syntometrine versus placebo during Emergency Caesarean secTION for the prevention of postpartum haemorrhage.

Start Date04 Mar 2019

Sponsor / Collaborator-

ChiCTR1800018488 / SuspendedPhase 4IIT

A multi-center, randomized, double-blind, controlled trial for revaluation of the effect of Ergometrine Maleate Injection in the prevention of postpartum hemorrhage

Start Date01 Oct 2018

Sponsor / Collaborator-

100 Clinical Results associated with Ergometrine Maleate

Login to view more data

100 Translational Medicine associated with Ergometrine Maleate

Login to view more data

100 Patents (Medical) associated with Ergometrine Maleate

Login to view more data

1,589

Literatures (Medical) associated with Ergometrine Maleate

01 Sep 2024·CLINICAL CARDIOLOGY

Lack of Class I Vasoreactivity Testing for Diagnosing Patients With Coronary Artery Spasm

Review

Author: Sakaue, Tomoki ; Ikeda, Shuntaro ; Sueda, Shozo ; Ono, Hiroki ; Okabe, Hikaru ; Hayashi, Yutaka

ABSTRACT:

Background:

Vasoreactivity testing, such as intracoronary acetylcholine (ACh) or ergometrine (EM), is defined as Class I for the diagnosis of patients with vasospastic angina (VSA) according to recommendations from the Coronary Vasomotion Disorders International Study (COVADIS) group and guidelines from the Japanese Circulation Society (JCS).

Hypothesis:

Although vasoreactivity testing is a clinically useful tool, it carries some risks and limitations in diagnosing coronary artery spasm.

Methods:

Previous reports on vasoreactivity testing for diagnosing the presence of coronary spasm are summarized from the perspective of Class I.

Results:

There are several problems such as reproducibility, underestimation, overestimation, and inconclusive/nonspecific results associated with daily spasm. Because provoked spasm caused by intracoronary ACh is not always similar to that caused by intracoronary EM, possibly due to different mediators, supplementary use of these vasoreactivity tests is necessary for cardiologists to diagnose VSA when a provoked spasm is not revealed by each vasoactive agent.

Conclusions:

Cardiologists should understand the imperfection of these vasoreactivity tests when diagnosing patients with VSA.

01 Jun 2024·Drug testing and analysis

Structural analysis of an lysergic acid diethylamide (LSD) analogue N‐methyl‐N‐isopropyllysergamide (MiPLA): Insights from Rotamers in NMR spectra

Article

Author: Kawamura, Maiko ; Tsuji, Genichiro ; Shoda, Takuji ; Demizu, Yosuke ; Kurohara, Takashi ; Misawa, Takashi ; Kikura-Hanajiri, Ruri

Abstract:

Lysergic acid diethylamide (LSD) is a hallucinogenic compound that binds to and activates the serotonin 2A receptor and is classified as a controlled narcotic in Japan. Recently, MiPLA, an N‐methyl‐N‐isopropyl derivative of LSD, has been detected in paper‐sheet products in several countries. This study focuses on the synthesis of MiPLA and includes a comprehensive analysis involving structural and liquid chromatography–mass spectrometry (LC‐MS). Particularly, MiPLA was synthesized in three‐steps starting from ergometrine maleate, which resulted in the formation of (8S)‐isomer, iso‐MiPLA, as a by‐product. The LC‐MS results showed that LSD, MiPLA, and iso‐MiPLA exhibited different retention times. Their chemical structures were determined using nuclear magnetic resonance spectroscopy, which revealed the presence of rotamers involving the N‐methyl‐N‐isopropyl groups of tertiary amides in MiPLA and iso‐MiPLA.

01 Apr 2024·European journal of obstetrics, gynecology, and reproductive biology

Preventing postpartum hemorrhage: A network meta-analysis on routes of administration of uterotonics

Review

Author: Daskalakis, Georgios ; Devall, Adam J ; Coomarasamy, Arri ; Antsaklis, Panos ; Tournas, Georgios ; Georgiopoulos, Georgios ; Papadopoulou, Argyro

OBJECTIVE:

To perform a network meta-analysis to specify the route of administration that maximises the effectiveness of each of the available prophylactic uterotonics without increasing the risk for side effects. 2.

DATA SOURCES:

Literature searches on 12th September 2022 included: CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. The reference lists of the retrieved study records were also searched. 3.

STUDY ELIGIBILITY CRITERIA:

Population: Randomized controlled trials involving women in the third stage of labour after a vaginal or caesarean delivery in hospital or community settings.

INTERVENTIONS:

Systemically administered prophylactic uterotonics of any route and dose for primary postpartum hemorrhage prevention. Comparison: Any other prophylactic uterotonic, or a different route or dose of a given uterotonic, or placebo, or no treatment. Outcomes (primary): postpartum hemorrhage ≥ 500 mL and ≥ 1000 mL. 4.

STUDY APPRAISAL AND SYNTHESIS METHODS:

Risk of bias and trustworthiness assessments were performed, according to Cochrane's guidance. Direct, indirect and network meta-analyses were conducted, and results were summarized either as risk ratio or mean difference with 95% confidence intervals for dichotomous and continuous outcomes, respectively. The certainty of generated evidence was assessed according to the GRADE approach. Cumulative probabilities were calculated and the surface under the cumulative ranking curve was used to create a ranking of the available drugs. 5.

RESULTS:

One hundred eighty-one studies involving 122,867 randomised women were included. Most studies were conducted in hospital settings in lower-middle income countries and involved women delivering vaginally. When compared with intramuscular oxytocin, carbetocin (RR 0.58, 95 % CI 0.40-0.84) and oxytocin (RR 0.75, 95 % CI 0.59-0.97) by an intravenous bolus, and intramuscular ergometrine plus oxytocin combination (RR 0.71, 95 % CI 0.56-0.91) are probably more effective in preventing primary postpartum hemorrhage. Intramuscularly administered oxytocin and carbetocin by an intravenous bolus have a favourable side effects profile. 6.

CONCLUSIONS:

Generated evidence was generally moderate and global inconsistency was low. Carbetocin and oxytocin by an intravenous bolus, and intramuscular ergometrine plus oxytocin combination are probably the top uterotonics for primary postpartum hemorrhage prevention. Large scale studies exploring different routes of administration for available prophylactic uterotonics, and women's views should be conducted.

100 Deals associated with Ergometrine Maleate

Login to view more data